Author:
Ducreux Michel,Lévi Francis
Publisher
Springer International Publishing
Reference49 articles.
1. Barnett KT, Malafa MP. Complications of hepatic artery infusion: a review of 4580 reported cases. Int J Gastrointest Cancer. 2001;30:147–60.
2. Rougier P, Ducreux M, Pignon JP, Elias D, Tigaud JM, Lumbroso J, Ruffie P, Lasser PH. Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. Eur J Cancer. 1991;27:1226–30.
3. De Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–15.
4. Kerr DJ, McArdle CS, Ledermann J, Taylor I, Sherlock DJ, Schlag PM, Buckels J, Mayer D, Cain D, Stephens RJ. Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. Lancet. 2003;361:368–73.
5. Munck JN, Riggi M, Rougier P, Chabot GG, Ramirez LH, Zhao Z, Bognel C, Ardouin P, Herait P, Gouyette A. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model. Cancer Res. 1993;53:1550–4.